Author: Marc Ethier

Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that the first patient has been dosed in Part 2 (randomized treatment expansion) of its ProstACT Global Phase 3 study evaluating its lead prostate cancer therapy candidate TLX591 (lutetium (177Lu) rosopatamab tetraxetan) in patients with metastatic castration resistant prostate cancer (mCRPC). The patient was dosed at the Australian Prostate Centre (APC) in Melbourne, Australia.Read More

Read More

As the Australian market experiences a tentative rise, with shares initially pointing towards gains before potential afternoon reversals, investors are closely monitoring economic indicators and broader market sentiment that could impact small-cap stocks. In this environment, identifying high-growth tech stocks involves looking for companies that can navigate these fluctuations effectively while capitalizing on technological advancements and strategic opportunities in the sector.Read More

Read More